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Objectives: Rapid rate-of-kill (RoK) is a key parameter in the target candidate profile 1 (TCP1) for the next-generation antimalarial drugs for uncomplicated malaria, termed Single Encounter Radical Cure and Prophylaxis (SERCaP). TCP1 aims to rapidly eliminate the initial parasite burden, ideally as fast as artesunate, but minimally as fast as chloroquine. Here we explore whether the relative RoK of the Medicine for Malaria Venture (MMV) Malaria Box compounds are linked to their mode of action (MoA) and identify scaffolds of medicinal chemistry interest. 
Methods: We used a Bioluminescence Relative RoK (BRRoK) assay over 6 and 48h, with exposure to equipotent-IC50 concentrations, to compare the cytocidal effects of Malaria Box compounds to benchmark antimalarials.
Results: BRRoK assay data demonstrate the following relative RoK from fast to slow: inhibitors of PfATP4 > parasite hemoglobin catabolism > DHFR-TS > DHODH > bc1 complex. Core scaffold clustering analyses reveal intrinsic rapid cytocidal action for diamino-glycerols and 2-(aminomethyl)phenol, but slow action for 2-phenylbenzimidazoles, 8-hydroxyquinolines, and triazolopyrimidines. 




Resistance by P. falciparum to front-line therapeutics necessitates new drugs with novel MoA to circumvent parasite resistance mechanisms.1,2 This need was initially met by the identification of 20,000 hits with sub-micromolar potency against P. falciparum intraerythrocytic stages from an extensive screening campaign of around four million compounds from the libraries of St. Jude Children's Research Hospital, TN, USA, Novartis and GSK. 2–6 Triaging these hits to establish development priorities requires additional pharmacodynamic information, key amongst which is their rate-of-kill (RoK).7 Rapid RoK is specifically identified by MMV as a key requirement within a future SERCaP to treat malaria.1,8 The target candidate profile TCP1 requires an immediate effect to rapidly eliminate parasites, minimally as fast as chloroquine and ideally as fast as artesunate. If resistance renders artemisinin ineffective, TCP1 candidates will ideally replace it.1,8




The transgenic Dd2 P. falciparum clone (Dd2luc)14,15 were cultured as described previously.7 The antimalarial drugs and the Malaria Box compounds were prepared as shown in Table S1. Malaria Box IC50 were measured in Dd2luc and deposited in the ChEMBL – Neglected Tropical Disease Open Access repository (ChEMBL3392923, see Van-Voorhis et al.,16).
The BRRoK48h assay was carried out as described previously7. Briefly, compounds were serially diluted (9× IC50, 3x IC50, 1x IC50 and 0.3× IC50 concentrations from a determination of IC50 at 48h) in 96-multiwell plates, trophozoite-stage (20–26 h post-infection) cultures of Dd2luc were added and mixed by pipetting to give a final 200 μL volume in each well with 3-fold IC50 dilution series of drugs, 1% parasitaemia and 2% haematocrit. To estimate the BRRoK48h, the plates were incubated continuously in the presence of the compounds for 48h prior to assay at 37°C. As described previously, 7,17 40 μL of P. falciparum culture were transferred to a white 96-multiwell plate (Greiner, UK) and lysed with 10 μL of passive lysis buffer (Promega, UK). An equal volume, 50 μL, of the supplied luminogenic substrate was mixed with the lysed parasites and the bioluminescence was measured for 2 s in a Glomax-Multi Detection System (Promega, UK). Experiments were carried out as technical triplicates on the same plate, with three independent biological repeats of each plate performed. Controls in each biological replicate consisted of trophozoite-stage culture with no drug added (100%) or uninfected erythrocytes (0%). The mean and standard deviation (SD) of bioluminescence data from three independent biological repeats were expressed as a proportion of the untreated control (100%) and calculated as follows: 100 × [μ(S) − μ (−)/μ (+) − μ (−)], where μ(S), μ (+) and μ (−) represent the means for the sample in question and 100% and 0% controls, respectively. The Z′ score of the BRRoK48h assay was calculated as follows: Z′ = 1 −  [(3σ(+) + 3σ(−))/μ(+) − μ(−)], where μ(+)and σ(+) are the mean and SD of the no-drug (untreated) positive control, respectively, and μ(−) and σ(−) are the mean and SD from uninfected erythrocytes (negative control), respectively.18 The signal/background (S/B) ratio was calculated as follows: [μ(+) − μ(−)]/σ(−). 




The BRRoK6h for the Malaria Box identifies compound clusters linked by common modes of antimalarial action 
That antiplasmodial in vitro RoK correlates with MoA has been established for a small number of antimalarial drugs, predominantly within classes that have been or are currently used.10 We have previously described a determination of the rates of initial cytocidal kill (over 6h) using the Bioluminescence Relative Rate of Kill (BRRoK) assay for 370 compounds from the Malaria Box open-access drug discovery resource relative to a range of benchmark antimalarials for which both in vitro and in vivo rates of kill data were available.7 This determination used a P. falciparum strain genetically modified to express a bioluminescent luciferase reporter protein, with cytocidal action determined by loss of bioluminescent signal following exposure to increasing concentrations of test compound. Analysis of the normalised concentration-dependant bioluminescent signals by principle components analysis provides for a rank of initial cytocidal action that enables rate of kill relative to known controls to be described. Termed PC1, for first principle component, these are presented as zero-meaned data where low values such as -97.4 relate to the extremely rapid acting dihydroartemisinin and higher values, such as 55.4, for the slow-acting atovaquone.7 
With BRRoK6h data for 370 Malaria Box compounds, we correlated these with MoA data made available as part of this open source drug discovery project (Figure 1).20–34  PC1 were plotted against their IC50 (ChEMBL3392923, see Van-Voorhis et al.,16) and mapped against benchmark antimalarials. Compounds with RoK ≥ dihydroartemisinin (DHA, PC1= -97.4) and ≥ chloroquine (CQ, PC1 = -73.7, log PRR= 4.5, 99% PCT= 32h) meet the TCP1 ideal and minimum essential criteria, respectively. Generally, compounds with RoK ≥ CQ are considered fasting acting, those with a RoK ≥ Quinine (QN, PC1 = -52), Mefloquine (MQ, PC1 = −42.4, log PRR = 3.7 and 99.9% PCT = 43 h) or Piperaquine (PQ, PC1 = -37, log PRR = 4.6, 99% PCT = 33h) are considered moderate acting, and those with RoK ≥ Atovaquone (ATQ, PC1 = 55.4, log PRR = 2.9 and 99.9% PCT = 90 h) are slow-acting (Figure 1, S1 Table). Thus, compounds with an initial rapid RoK and nM potency, like artemisinins, occupy the bottom-left quadrant those such as atovaquone, whilst potent, being slow-acting occupies the upper left-hand quadrant (Figure 1). 
MoA data was sourced from specific activity assays (e.g. in vitro enzyme inhibition assays) to comparative metabalomic profiling, and as such the MoA association for the Malaria Box are often tentative. We hypothesized that compounds with a shared MoA would exhibit similar BRRoK6h data. Five MoA including compounds targeting (i) PfATP4, a Na+-ATPase in the parasite’s plasma membrane, ii) bifunctional Plasmodium enzyme dihydrofolate reductase-thymidylate synthase (DHFR-TS), (iii) dihydroorotate dehydrogenase (DHODH), (iv) the bc1 complex of the mitochondrial electron transport chain and (v) parasite hemoglobin catabolism (Figure 1A-E) were clustered. These MoA were selected because in vitro PRR data are available for > 10 compounds (Table S2) in each class.16,20,21,27,28,35 RoK were identified from fast to slow: PfATP4 > parasite hemoglobin catabolism > DHFR-TS > DHODH > bc1 complex. Using one-way ANOVA with a post-hoc Tukey test 7,16,20,29,30, we found that compounds targeting PfATP4 exhibit the fastest RoK and are significantly faster than other clusters (Figure 1F). Compounds targeting parasite hemoglobin catabolism are significantly faster than those targeting DHFR-TS, DHODH and bc1 complex, and compounds targeting DHFR-TS are faster than DHODH and bc1 complex inhibitors (all p < 0.01), while other pairwise comparisons are not significant. 
BRRoK6h highlights rapid cytocidal activity for diamino-glycerols and 2-(aminomethyl)phenol scaffolds in the Malaria Box
The Malaria Box compounds were selected to be structurally diverse.2 We wished to determine whether substructure analysis of these novel Malaria Box compounds reveals novel core scaffolds with shared RoK activity, and thus potentially with new MoA. BRRoK6h data was overlaid with five distinct scaffolds; diamino-glycerols, 2-(aminomethyl)phenol, 2-phenylbenzimidazole, 8-hydroxyquinolines, and triazolopyrimidine (Figure 2). Table S3 shows full structures and the core scaffold substructures, with > 5 compounds for each scaffold annotated. We found a fast BRRoK for diamino-glycerols and 2-(aminomethyl)phenols, and slow BRRoK for 2-phenylbenzimidazoles, 8-hydroxyquinolines and triazolopyrimidines (Figure 2A-E). The five core scaffolds identified BRRoK ranking from fast to slow: diamino-glycerols > 2-(aminomethyl)phenol > 2-phenylbenzimidazole > 8-hydroxyquinolines > triazolopyrimidine. The diamino-glycerol scaffold exhibited the fastest cytocidal action among the group (p < 0.01 for all, except 2-(aminomethyl)phenol where p > 0.05 by ANOVA (Figure 2F). Similarly, compounds in the 2-(aminomethyl)phenol scaffold exhibited significantly faster action (p < 0.01) than the 2-phenylbenzimidazole, 8-hydroxyquinolines and triazolopyrimidine scaffolds (Figure 2F).
BRRoK48h confirms slow cytocidal action for a subset of compounds in the Malaria Box 
The BRRoK6h assay identified fast-acting Malaria Box compounds as TCP1 candidates, including the fastest-acting PfATP4 inhibitor spiroindolone MMV396749 (Table S2). However, almost half of the Malaria Box showed little cytocidal activity against intraerythrocytic trophozoites over 6h. We predicted that these compounds might have a lag phase in their cytocidal action, such as shown by the antimalarial atovaquone with a 48h lag in cytocidal action.10 We therefore employed a revised BRRoK assay over 48h (BRRoK48h) to ensure completion of one full intraerythrocytic cycle. For validation, we selected different benchmark antimalarials, which covered multiple MoA.7 Dd2luc parasites were exposed to a 3-fold serial dilution (9–0.33 × IC50) for 48h, the resulting bioluminescence signal normalized to an untreated control, and the normalized bioluminescent signal plotted against drug concentration (Figure S1). We found the identical relative ranking order of benchmark antimalarial drugs (i.e. artemisinin > chloroquine > 4-methanolquinolines > atovaquone) to  BRRoK6h,7 which is identical to both the in vivo and in vitro RoK.31–33,35 
We had sufficient material available for 178 slow-acting Malaria Box compounds. Along with the benchmark antimalarial drugs ATQ, CQ, DHA, MQ, PPQ, pyronaridine (PYN) and QN, we subjected them to a BRRoK48h assay (Table S4; Figures S2, S3). 95% confidence intervals for the Z′ score (0.85-0.95), maximum coefficient of variation (0.9%-2.84%), and signal/background ratio (2580-5001) indicate a robust and sensitive microplate-based assay of the BRRoK48h data. Using mean ± SD for each IC50-fold BRRoK48h normalized bioluminescent signal, a PCA was carried out for concentration-dependent effects (Figure S4; Tables S5-S6). PC1 accounts for 78% of the variance at 48h, with most contributions provided by the 3X IC50 data. 




The next-generation antimalarial drugs should rapidly eliminate parasite burden, ideally as fast as artesunate, but at least as fast as chloroquine.1 Whilst we have previously used the BRRoK6h assay to measure the relative RoK for 370 Malaria Box compounds, here we show that BRRoK6h data provides links to the antimalarial MoA (with PfATP4 > parasite hemoglobin catabolism > DHFR-TS > DHODH > bc1 complex) and that comparison with scaffold sub-structures identified five core scaffolds with the relative RoK: diamino-glycerols > 2-(aminomethyl)phenol > 2-phenylbenzimidazole > 8-hydroxyquinolines > triazolopyrimidine. We also predicted that compounds with minimal activity at 6h might have a lag phase, like atovaquone and DSM265.7,10,35 Thus, we determined the RoK of apparently slow-acting compounds using a BRRoK48h assay and show that many of the slow-acting compounds are likely DHODH and bc1 complex inhibitors.  In short, compounds in the Malaria Box with similar targets and chemical core substructure exhibit similar time-dependant RoK dynamics. Although our study is limited to a library of 400 compounds that lack a full biochemical target validation, it provides the proof-of-principle that BRRoK data offers an opportunity to rapidly prioritize compounds in the TCAMS, or other, library by informing predictions of structure-activity and MoA. Moreover, we note that using the BRRoK assay at two-time points, 6 and 48h, we not only have the potential to rapidly identify and discriminate between compounds that meet the ideal and minimum TCP1 criteria, but also identify compounds that likely exhibit a lag time in drug action between 6 and 48h. This BRRoK assay format, however, does not provide a reliable assessment of the extent and timing of this lag time, as would be reported by a recrudescence assay.10 
A compound’s immediate cytocidal activity likely results from the nature of the target and the ease of access to the target. The first aspect considers how quickly a deficit in this target’s function will lead to cell death – i.e. its MoA. In vitro assays of RoK report that antimalarial drugs with a similar MoA result in similar RoK.7,10 We have significantly extended this observation here for the open Source Malaria Box, a critical collection of antimalarial drug discovery compounds. Whilst an important caveat is that for most compounds described the target association is tentative, this library is still the best described and investigated resource in this endevour.21 Nonetheless, here we were able to consider five MoA groups due to availability of  in vitro PRR data and at least 10 MMV compounds annotated for each MoA from a range of sources.16,20,21,27,28,35 Specifically; (i) PfATP4 (Figure 1A): 33 compounds are annotated as PfATP4 inhibitors (Figure 1A).20,29 In vitro PRR data are available for exemplar PfATP4 inhibitors (+)-SJ733,3621 a dihydroisoquinoline with a slow-to-moderate RoK, and KAE609/NITD609,27 a spiroindolone with a moderate to fast RoK. Most potential Malaria Box PfATP4 inhibitors were reported as having a BRRoK6h between the moderate mefloquine 10 (comparable to the PRR reference pyrimethamine10) and the rapidly-acting dihydroartemisinin. The fastest-acting PfATP4 inhibitor was the spiroindolone MMV396749, with several studies reporting a fast to moderate cytocidal activity for PfATP4 inhibitors.7,16,20,21,27,29 The Malaria Box also contains five structural analogues of the slower acting PfATP4 inhibitor (+)-SJ733; two have PC1s falling between the fast-acting dihydroartemisinin and chloroquine with the remaining three between mefloquine and atovaquone, supporting the prediction of a moderate to slow RoK of the dihydroisoquinolines. (ii) Plasmodium dihydrofolate reductase-thymidylate synthase (DHFR-TS) (Figure 1B): 14 compounds are annotated as DHFR-TS inhibitors, clustering with known antifolate antimalarial drugs that target DHFR-TS, P218, pyrimethamine, and WR99210.29,40–42 Pyrimethamine has a lag phase of 24 h, which is the slowest RoK after ATQ.10 The BRRoK6h confirms slow cytocidal activity for this cluster, between slow-acting atovaquone and moderate-acting pyronaridine. (iii) Dihydroorotate dehydrogenase (DHODH) (Figure 1C): 43 compounds are annotated as DHODH inhibitors, and BRRoK6h show that they share a slow initial cytocidal action. This slow RoK correlates with the atovaquone-like in vitro PRR data for DSM26535, due to its 24-48h lag phase. One outlier, MMV666102, falls between pyronaridine and mefloquine showing a slow-to-moderate cytocidal action. Whilst no additional target information is available, we predict that this compound may have additional targets. (iv) bc1 complex inhibitors: 18 compounds are annotated as bc1 complex inhibitors and are slowly cytocidal in the BRRoK6h and are comparable to atovaquone which shares the same MoA.10 Comparing BRRoK with the predicted MoA for all four groups indicates that compounds with a similar MoA have similar RoK. The predicted MoA used here was primarily obtained through metabolomics16,29,30 and readily highlights the potential for BRRoK to complement such studies. (v) Parasite hemoglobin catabolism: Allman et al.,29 reports a compound group in the Malaria Box that perturbs parasite hemoglobin catabolism. Parasite hemoglobin catabolism compounds formed our second fastest-acting cluster (Figure 1E). However, as expected, the BRRoK6h data reveals a broad RoK range for these compounds, which agrees with metabolomics data, as these compounds have a range of predicted targets. For example, chloroquine, known for accumulation within the digestive vacuole of Plasmodium, clusters with this group, but the resulting metaprint is divergent, due to the overall lack of significant metabolic changes or dysregulation induced by chloroquine.29,43 MMV390048, which inhibits the phosphatidylinositol 4-kinase (PI4K), and AZ412, which inhibits the putative vacuolar ATPase,12,29,44 also clusters with this group. Interestingly, as expected from compounds with different targets, the BRRoK6h appears to form subclusters within this group. Upon additional target data availability, we would predict that this currently broad class of compounds could be further categorised into slow, moderate, and fast-acting groups.
A second means to classify compounds for comparison to the BRRoK6hr data is through their chemical structure (Figure 2). Our analysis suggests that structurally similar compounds exert a similar RoK. This is not surprising if they share the same target, and our analysis suggests that medicinal chemistry may not only improve IC50 potency for candidates but may also help improve RoK within chemical class and a well-defined MoA. For example, all five triazolopyrimidine scaffold members (Figure 2A) inhibit DHODH and are structural analogs of DSM265, a known slow-acting compound in clinical trials.35 However, their PC1 varies between 23 and 67, highlighting room to influence the initial cytocidal action within the limits of this chemical class and the intrinsic limits of the MoA. A range of slow cytocidal activity is also reported for 8-hydroxyquinolines (PC1 of 8.8-95.4) (Figure 2B), with one annotated as a DHODH inhibitor. We also report two fast-acting scaffolds: diamino-glycerols and 2-(aminomethyl)phenol (Figure 2C-D).  The diamino-glycerol is the fastest scaffold described here, which agrees with a predicted MoA as four of these nine compounds are PfATP4 inhibitors.16,20,29 It would be interesting to investigate whether the remaining five compounds also affect PfATP4. Three of these five compounds are designated as probe-like and were not characterised in metabolomic studies that focussed on drug-like compounds in the Malaria Box.29 Furthermore, five compounds are structurally related to the amino alcohol-carbazoles, which has demonstrated long-lasting and fast-acting antimalarial activity in vivo,45 in agreement with BRRoK6h measurements here. The next most fast-acting compound cluster is the 2-(aminomethyl)phenol scaffold. Interestingly, BRRoK6h indicated five of 14 compounds in this scaffold are likely inhibitors of parasite hemoglobin catabolism (PC1 between -79 and -51),29 which is the second fastest-acting compound cluster according to MoA comparisons and agrees with our chemical clustering analyses. Eight compounds are probe-like, so metabolomic data are not available, however, Creek et al.43 have shown an artemisinin-like metabolomic signature for three of these compounds, thus confirming the relative fast action of this scaffold. These data illustrate how BRRoK data can be effectively employed alongside other datasets to inform how decisions are made regarding the selection of targets for further study and/or development.
Given the short timeframe of the BRRoK6h, a second attribute that may influence RoK is ease of target access. Within our in vitro assay, compounds must migrate through up to four membranes to access a target within an infected erythrocyte and the biophysical parameters of size, hydrophobicity, hydrogen-bonding capabilities and charge may contribute to how easily access occurs. Another consideration for compounds with a basic charge at physiological pH, is that of access/accumulation within the digestive vacuole in the trophozoite, irrespective of the final target site. Biophysical properties span charge type, lipophilicity, polarity, size, 3D-shape, flexibility and H-bond properties.46 To investigate what influence molecular properties have on BRRoK6h, we calculated key biophysical properties for Malaria Box compounds (PC1) (Table S8) and compared compounds with relative RoK faster than DHA and slower than atovaquone to see if extremes of RoK are associated with significantly different molecular properties. We expanded analyses to include compounds reported to have a common, fast MoA (PfATP4), a common, slow MoA (bc1 complex), a common fast core (2-(Methylamino)-Phenols, 2-MAP), and a common, slow core (2-Phenylbenzimidazoles, 2-Ph-Bz) (Table S8-9). These analyses do not reveal molecular property differences associated with BRRoK, although an important limitation here are the numbers of compounds in each group. Finally, we compared individual compounds with the fastest BRRoK6h and slowest BRRoK6h in the five MoA clusters investigated here and found some small differences (Table S10). The fastest compound in each MoA often has a lower MW, less rotatable bonds and is more aromatic in nature compared to the slowest, suggesting that careful biophysical property control may allow compound design to achieve improvements in RoK within a well-defined MoA/chemical class.
Perhaps the key benefit of RoK analysis considering both the MoA and chemical substructure is that outliers emerge that would appear to warrant additional validation or follow up. An example from this study are the three 1,2-diaza-9-fluorenones (MMV666021, MMV6666026 and MMV665934) for which the proposed MoA is the bc1 complex, which would imply a very slow RoK. However, we instead found that two of these have very fast BRRoK. Also, of interest is the structural singleton MMV142383, which has the fastest RoK (PC1= -131.5) and is categorised as acting by hemoglobin catabolism. Exceptions found using sub-structure analysis may have either miscategorized MoA or alternatively, they may have more than one MoA. The latter would be of particular interest as would theoretically lead to less resistance if more than one target is involved. 
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Figure 1.  Correlating mode of drug action with the BRRoK6h in the MMV Malaria Box compounds. 










Figure 3. Distribution of BRRoK (PC1) against IC50 for the MMV Malaria Box compounds.
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